Business Wire

71% of Global Businesses Have Accelerated AI Adoption Amid Tariffs, Inflation and Uncertainty, Finds Economist Study Commissioned by Kinaxis

10.11.2025 14:00:00 EET | Business Wire | Press release

Share

According to Supply Chain’s Big Bet on AI For Geopolitical Resilience, a new global study from Economist Impact, commissioned by Kinaxis® Inc. (TSX:KXS), while 71% of companies have accelerated AI deployment in response to tariffs, inflation, and geopolitical volatility, a wide gap remains between AI ambition and implementation, according to Economist Impact.

Nearly every company (97%) is experimenting with AI, but only 20% can make real-time decisions, and just 22% have a defined AI strategy, and those with one are more than three times as likely to see measurable ROI. Moreover, while business leaders tend to underestimate the new risks and complexities that AI may introduce, staff are more focused on the practical realities with the effort, change management, and technical challenges involved in turning AI ambition into everyday impact.

“Disruption is no longer cyclical, it’s structural, and AI has become the defining accelerator of adaptability,” said Fab Brasca, Senior Vice President, Market Strategy and Product Management at Kinaxis. “In a world of constant geopolitical and economic turbulence, companies cannot afford to experiment in isolation or chase hype. Those that orchestrate intelligence across the enterprise, by turning data into continuous decisions, will convert volatility into advantage.”

Adoption Is Up, But Action Lags

AI adoption varies widely by use case, revealing where companies are focusing their early efforts - and where critical blind spots remain.

  • 52% of organizations report full integration for predictive analytics (the leading use case)
  • Fewer than 15% of companies use AI for supplier monitoring, anomaly detection, or geopolitical tracking, the very risks now driving adoption. 

At the same time, economic pressure is amplifying the urgency to act as companies face rising costs and supply instability.

  • 79% of companies have already passed higher costs on to consumers
  • More than three-quarters report worsening availability of key components 

Inside organizations, a confidence gap is emerging between leadership optimism and day-to-day execution.

  • Two-thirds of C-suite executives expect AI to deliver returns within 12 months
  • Less than 50% of junior leaders share that view

Regional Contrasts Are Clear

  • Executives in Asia-Pacific (81%) and Europe (78%) report faster AI acceleration than those in North America (57%)
  • Executives in Europe (38%) and Asia-Pacific (31%) report stronger AI investment momentum than those in North America (22%), reflecting differences in regulatory environments and risk appetite
  • Even in the fastest-moving regions, adoption remains shallow - just 11% use AI for scenario modeling and only 3% for geopolitical tracking.

The Blind Spot - Readiness and Governance

Fewer than one in four business leaders expect AI-related risks to increase over the next three years, revealing a major gap between confidence and capability. While companies are rapidly deploying AI to manage geopolitical and economic shocks, most are not addressing the underlying challenges of data readiness, governance, and accountability that will determine whether those investments pay off.

“The data reveal how far ambition has outpaced readiness,” said Oliver Sawbridge, senior manager, trade, and geopolitics at the Economist. “Companies are racing to deploy AI to manage geopolitical and economic shocks, but most lack the data, systems, and strategies to make it work in real time. It is a reminder that resilience depends as much on preparedness as on innovation.”

This growing disconnect highlights a key theme across the study: as AI moves from experimentation to execution, the ability to govern and scale it responsibly will define who turns adoption into advantage.

The Kinaxis View: From Automation to Adaptation in the new Agentic Age

Fewer than one in ten organizations have begun exploring agentic AI. That is where Kinaxis sees the next frontier - using AI as a foundation for adaptability, where agents and humans orchestrate together, continuously, safely, and in context. Powered by concurrency and governance guardrails, every recommendation is explainable, every action auditable, and every decision aligned to business outcomes.

The findings from Supply Chain’s Big Bet on AI For Geopolitical Resilience reinforce this vision. Real resilience is not automation for efficiency’s sake, it is intelligent adaptation. It is the difference between AI that reacts to disruption and AI that helps organizations stay ahead of it: a future built on agentic orchestration, where planning and execution move together to turn volatility into foresight and adaptability into growth.

Learn more

Download and read the full report here:www.kinaxis.com/en/economist-ai

Register for the live webinar with Kinaxis and Economist Impact on November 20 at 11 a.m. ET.

About the Study

The report is based on a survey of more than 800 senior business leaders across Europe, North America, and Asia-Pacific. Economist Impact conducted the research independently, with sponsorship from Kinaxis.

About Kinaxis

Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains, and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

Source: Kinaxis Inc

View source version on businesswire.com: https://www.businesswire.com/news/home/20251110649522/en/

Contacts

Media Relations
Matt Tatham | Kinaxis
mtatham@kinaxis.com
+1 917-446-7227

Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
+1 613-907-7613

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye